Known targets — ChEMBL curated mechanism
BRAFFLT1FLT3FLT4KDRKITPDGFRBRAF1RET
The experimentally established mechanism targets of Cm-4307. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAF1 known ✓ | P04049 | 12/20 | 0.88 |
| ▸ | KDR known ✓ | P35968 | 5/20 | 0.88 |
| ▸ | BRAF known ✓ | P15056 | 4/20 | 0.88 |
| ▸ | RET known ✓ | P07949 | 3/20 | 0.88 |
| ▸ | PDGFRB known ✓ | P09619 | 2/20 | 0.88 |
| ▸ | KIT known ✓ | P10721 | 2/20 | 0.88 |
| ▸ | FLT1 known ✓ | P17948 | 2/20 | 0.88 |
| ▸ | FLT4 known ✓ | P35916 | 2/20 | 0.88 |
| ▸ | FLT3 known ✓ | P36888 | 2/20 | 0.88 |
| ▸ | RIPK2 | O43353 | 2/20 | 0.88 |
| ▸ | ABCB11 | O95342 | 2/20 | 0.88 |
| ▸ | ABL1 | P00519 | 2/20 | 0.88 |
| ▸ | HTR1A | P08908 | 2/20 | 0.88 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.88 |
| ▸ | FGFR1 | P11362 | 2/20 | 0.88 |
| ▸ | PDGFRA | P16234 | 2/20 | 0.88 |
| ▸ | MAOA | P21397 | 2/20 | 0.88 |
| ▸ | EPHA1 | P21709 | 2/20 | 0.88 |
| ▸ | TBXA2R | P21731 | 2/20 | 0.88 |
| ▸ | EPHA2 | P29317 | 2/20 | 0.88 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Cm-4307 SCHEMBL29362075 | 1.00 | RAF1 (0.88) | RAF1KDRBRAFRETRIPK2 | |
| Cm-4307 SCHEMBL14480690 | 1.00 | RAF1 (0.88) | RAF1KDRBRAFRETRIPK2 | |
| Sorafenib SCHEMBL14481281 | 0.95 | RAF1 (0.89) | RAF1KDRBRAFRETRIPK2 | |
| Sorafenib SCHEMBL14481164 | 0.94 | RAF1 (0.88) | RAF1KDRBRAFRETRIPK2 | |
| Sorafenib SCHEMBL14550501 | 0.94 | RAF1 (0.77) | RAF1KDRBRAFRETRIPK2 | |
| Sorafenib SCHEMBL8218 | 0.93 | RAF1 (1.00) | RAF1KDRBRAFRETRIPK2 | |
| Sorafenib SCHEMBL29349634 | 0.93 | RAF1 (1.00) | RAF1KDRBRAFRETRIPK2 | |
| Sorafenib SCHEMBL14739751 | 0.93 | RAF1 (1.00) | RAF1KDRBRAFRETRIPK2 | |
| Sorafenib SCHEMBL1533976 | 0.93 | RAF1 (0.98) | RAF1KDRBRAFRETRIPK2 | |
| Sorafenib SCHEMBL1533982 | 0.93 | RAF1 (0.98) | RAF1KDRBRAFRETRIPK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4536285-A2 | METHODS AND COMPOSITIONS FOR INITIATING, REGULATING, AND MODULATING WEIGHT LOSS AND THERAPEUTIC APPLICATIONS THEREOF | Kojin Therapeutics, Inc. (US) | 2025-04-16 | — | — | EP | claimed |
| EP-4460299-A2 | METHODS AND COMPOSITIONS FOR INDUCING FERROPTOSIS IN VIVO | Kojin Therapeutics, Inc. (US) | 2024-11-13 | — | — | EP | claimed |
| WO-2023240204-A2 | METHODS AND COMPOSITIONS FOR INITIATING, REGULATING, AND MODULATING WEIGHT LOSS AND THERAPEUTIC APPLICATIONS THEREOF | Kojin Therapeutics, Inc. (US) | 2023-12-14 | — | — | WO | claimed |
| US-20230226185-A1 | METHODS AND COMPOSITIONS FOR INDUCING FERROPTOSIS IN VIVO | Kojin Therapeutics, Inc. | 2023-07-20 | — | — | US | claimed |
| WO-2023133053-A2 | METHODS AND COMPOSITIONS FOR INDUCING FERROPTOSIS IN VIVO | Kojin Therapeutics, Inc. (US) | 2023-07-13 | — | — | WO | claimed |
| US-20260034094-A1 | COMPOSITIONS AND METHODS FOR INDUCING FERROPTOSIS | KOJIN THERAPEUTICS INC (US) | 2026-02-05 | — | — | US | disclosed |
| EP-4565228-A2 | COMPOSITIONS AND METHODS FOR INDUCING FERROPTOSIS | Kojin Therapeutics, Inc. (US) | 2025-06-11 | — | — | EP | disclosed |
| EP-4536285-A2 | METHODS AND COMPOSITIONS FOR INITIATING, REGULATING, AND MODULATING WEIGHT LOSS AND THERAPEUTIC APPLICATIONS THEREOF | Kojin Therapeutics, Inc. (US) | 2025-04-16 | — | — | EP | disclosed |
| EP-4460299-A2 | METHODS AND COMPOSITIONS FOR INDUCING FERROPTOSIS IN VIVO | Kojin Therapeutics, Inc. (US) | 2024-11-13 | — | — | EP | disclosed |
| WO-2024030960-A2 | COMPOSITIONS AND METHODS FOR INDUCING FERROPTOSIS | Kojin Therapeutics, Inc. (US) | 2024-02-08 | — | — | WO | disclosed |
| WO-2023240204-A2 | METHODS AND COMPOSITIONS FOR INITIATING, REGULATING, AND MODULATING WEIGHT LOSS AND THERAPEUTIC APPLICATIONS THEREOF | Kojin Therapeutics, Inc. (US) | 2023-12-14 | — | — | WO | disclosed |
| US-20230226185-A1 | METHODS AND COMPOSITIONS FOR INDUCING FERROPTOSIS IN VIVO | Kojin Therapeutics, Inc. | 2023-07-20 | — | — | US | disclosed |
| WO-2023133053-A2 | METHODS AND COMPOSITIONS FOR INDUCING FERROPTOSIS IN VIVO | Kojin Therapeutics, Inc. (US) | 2023-07-13 | — | — | WO | disclosed |
| US-11541116-B1 | Methods and compositions for inducing ferroptosis in vivo | Kojin Therapeutics, Inc. (US) | 2023-01-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230226185-A1 | METHODS AND COMPOSITIONS FOR INDUCING FERROPTOSIS IN VIVO | AIFM2, GPX4, SLC40A1 | RAF1 1371/4885KDR 4574/4885BRAF 1008/4885 |
| US-20260034094-A1 | COMPOSITIONS AND METHODS FOR INDUCING FERROPTOSIS | AIFM2, GPX4, HMOX1 | RAF1 758/4885KDR 3229/4885BRAF 898/4885 |
| US-11541116-B1 | Methods and compositions for inducing ferroptosis in vivo | AIFM2, GPX4, SLC40A1 | RAF1 1371/4885KDR 4574/4885BRAF 1008/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.